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Soluble CD14 (sCD14) mediates lipopolysaccharide (LPS) activation of epithelial cells in vitro
and may thereby be harmful in sepsis. sCD14 function was analyzed in sera from 62 patients with
septic shock and compared with data from appropriate controls. sCD14 function was measured as
sCD14-dependentLPS-induced interleukin (IL)-8 release in the SW620epithelial cell line. In these
cells, IL-8 production correlated with LPS concentration and the amount of sCD14. The effect of
natural or recombinant sCD14 was maximal at 100 ng/mL and blocked by anti-CD14 antibodies.
Patient and control sera (0.5% final concentration) promoted induction of IL-8 by 100 ng/mL LPS
in SW620 cells. In sepsis patients (highest serum sCD14), values were significantly higher than in
the other groups. The LPS-induced IL-8 response was blocked by anti-CD14 and correlated with
the serum CD14 level in sepsis patients. Thus, sCD14 could playa pathogenetic role in sepsis.
Lipopolysaccharide (LPS) plays a key role in gram-negative
sepsis. It binds to membrane CDl4 (mCDl4) on myeloid cells
and to soluble CDl4 (sCDl4) in serum [1, 2]. LPS bound to the
glycosyl-phosphatidylinositol (GPI)-linked mCDl4 promotes
monocyte activation via tyrosine phosphorylation of several
kinases [3-5]. The LPS-sCDI4 complex activates endothelial
and epithelial cells, which are devoid of mCD14, via an un-
known receptor [6-8]. sCDl4 also acts on myeloid cells; it
was shown to compete with mCD 14 for LPS binding and to
reduce LPS-induced cytokine production in monocytes and
macrophages [9]. We have recently shown that patients with
gram-negative septic shock have increased levels of sCDl4
that are associated with high mortality [10]. However, the
pathogenetic role of sCDl4 in sepsis is unknown.
mCDl4 is a 54-kDa glycoprotein [11] that was initially
known as a myeloid differentiation marker [12]. sCD14 is re-
leased in two isoforms (49 and 55 kDa) from monocytes, both
lacking the GPI anchor [10, 13, 14]. The smaller form is derived
from the membrane by proteolytic cleavage and therefore has
a shortened C-terminus without a GPI anchor. The larger form
is directly released from an intracellular source, without attach-
ment of a GPI tail [13-16]. In serum of healthy volunteers,
we found only the 49-kDa form. In contrast, in patients with
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septic shock, we detected either form, provided that their CD14
level was <3.5 mg/mL. However, sera from patients with high
sCDl4 levels (>3.5 mg/mL) contained exclusively the larger
55-kDa form [10]. Myeloid cells from patients with paroxysmal
nocturnal hemoglobinuria (PNH) lack mCDI4, since they have
an acquired deficiency in the synthesis of the GPI anchor [17].
Nevertheless, their serum contains normal amounts of sCDl4
of the larger isoform, presumably from an intracellular source
[10]. Serum of these patients can be used to study the function
of the large isoform of sCD 14.
We analyzed the function of sCD14 in patients with septic
shock. In addition, we asked whether there was a functional
difference between the two sCD14 isoforms. For this purpose,
we studied the effect of serum sCD14 on LPS-induced interleu-
kin (IL)-8 release in an epithelial cell model. Sera from patients
with PNH, who display only the large isoform, and from
healthy controls, who all display the small isoform, were com-
pared with those from patients with sepsis. The epithelial cell
model was chosen because measurements are more reproduc-
ible in a cell line than in primary cultures (e.g., of endothelial
cells). Moreover, epithelial cells are also involved in inflamma-
tion during sepsis by secreting cytokines [18], and disturbed
alveolar epithelial cell function participates in the pathogenesis
of acute respiratory distress syndrome [19]. In addition, IL-8
serum levels are often elevated in sepsis [20], and the increased
concentrations in these patients may originate from an in vivo
effect of LPS and sCD14 on epithelial cells. Therefore, we
analyzed whether CD 14 in serum from sepsis patients could
mediate LPS-induced IL-8 production in an epithelial cell line.
Methods
Patients. The study population consisted of 69 patients (45
male, 26 female) with septic shock, who were part of a previously
published study comparing the efficacy of J5-hyperimmuno
globulin (n = 30) with standard IgG (n = 39; Sandoglobulin;
Sandoz, Basel, Switzerland) [21]. Fifty-three patients had gram-
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negative sepsis and 16 had gram-positive or fungal sepsis or no
bacteriologic documentation. The median age was 56 years (range,
7- 78). In all patients, blood was sampled at study entry, at which
time the median arterial blood pressure was 90/50 mm Hg and the
median duration of shock was 10 h (range, 2-144). Sera were
aliquoted and kept at - 70°C until use. In addition, 6 patients (2
men, 4 women) with PNH (ages 24-49 years; median, 32) and
11 healthy controls (7 men, 4 women; ages 29-73 years; median,
51) were studied.
Reagents. LPS of Salmonella abortus equi (smooth) and Esch-
erichia coli Re 595 (rough) and lipid A were gifts of C. Galanos
(Max Plank Institut, Freiburg, Germany). The following purified
antibodies were used: MEM18 (IgGl; gift ofV. Bazil, Institute of
Molecular Genetics, Prague) [22], RoMol (IgG2a; IBL, Hamburg,
Germany), and goat polyclonal anti-CD14 antiserum (gift of R.
Ulevitch, Scripps Research Institute, La Jolla, CA). Mouse mono-
clonal antibodies 3ClO (IgG2b, ATCC TIB 228) and 6303 (IgGl,
ATCC HB44) directed against CDl4 were purified by affinity
chromatography from hybridoma culture supernatants. Affinity-
purified IgG2b from an irrelevant monoclonal mouse antibody
(ATCC TIB94 anti-Ia") served as control. Human serum was a
pool from 5 healthy donors. It contained 2.61 jLg/mL sCD14; it
was not heat-inactivated because sCDl4 is destroyed by 30 min
of incubation at 56°C (data not shown). The serum contained LPS-
binding protein (LBP), as it allowed LPS-binding to monocytes
sensitive to anti-LBP antiserum [23]; the LBP level was 5.7 jLg/
mL (determined by P. Tobias, Scripps Research Institute). sCD14
was immunodepleted from serum by adsorption to 63D3-coupled
CNBr-Sepharose. After centrifugation, the serum contained no de-
tectable sCD14, as determined in a CDl4 ELISA [10].
Recombinant (r) sCD14 production and purification. Oligonu-
cleotide primers (sense, AGCACTTCCAGAGCCTCTCC; anti-
sense, GCAGCACCAGGGTTCCCGAC) were used to amplify a
1135-bp product. Plasmid that contained eDNA-encoding human
CD14 served as a template (gift ofR. Ulevitch). The PCR product
was cloned into a eukaryotic expression vector (pRe, Invitrogen;
Inotech, Dottikon, Switzerland). The expression construct was
used to stably transfect CHO cells. Transfectants released 10 jLg
of sCD141106 cells/24 h. rsCD14 was purified by immunoaffinity
chromatography. For this purpose, anti-CD14 antibody 3ClO,
which does not compete with LPS for binding to sCDl4 [24], was
coupled to CNBr-activated Sepharose 4B (Pharmacia, Diibendorf,
Switzerland). After treatment with 1 M ethanolamine (pH 8.0) for
2 h at room temperature, the Sepharose resin was washed with
TRIS buffer at increasing pH and molarity, treated with triethanol-
amine (pH 11) to eliminate nonspecifically bound antibody, and
finally neutralized with PBS. The supernatant of transfeeted CHO
cells, which had been cultured in RPMI medium with 2% fetal
calf serum (FCS; GIBCO, Grand Island, NY) and 100 jLg/mL
Geneticin (Boehringer, Mannheim, Germany), was adsorbed to
3ClO-CNBr-Sepharose overnight at 4°C. After a wash with 50
mM TRIS buffer (pH 8.0), elution with 50 mM glycine buffer (pH
3.5) was started. The eluted fractions were tested for sCDl4 by
ELISA and Western blotting as described [10]. They did not con-
tain any murine IgG. rsCD14 was aliquoted in PBS and stored
at -70°C.
ELISA of sCD14. Concentrations of sCD14 in sera from pa-
tients with sepsis were determined as described [10] by using the
donated or commercially available anti-CD14 antibodies MEMl8
and peroxidase-labeled RoMo1 with a calibrated serum as a stan-
dard. rsCDl4 was analyzed by an ELISA that was developed in
our laboratory with the use of anti-CDl4 antibodies 63D3 (2 f.-lg/
mL) and peroxidase-labeled 3ClO (500 ng/mL).
sCD14 functional assays. SW620 cells (adenocarcinoma,
ATCC CCL227) were maintained in RPMl 1640 with 10% heat-
inactivated FCS supplemented with gentamicin. For the functional
tests, cells were seeded into 96-well microtiter plates at 4 X 104
cells/well and grown overnight. The cells were then washed twice
in serum-free medium and stimulated the next 6 h with LPS in
the presence of2% human serum albumin or serum with or without
the addition of antibodies.
IL-8 ELISA. Culture supernatants were harvested from the
SW620 cells, centrifuged to eliminate cell debris, and kept at
- 20°C for the determination of IL-8. Monoclonal anti- IL-8 anti-
bodies (5 f.-lg/mL; provided by P. Stuetz, Sandoz) were coated onto
96-well polystyrene plates (Greiner, Frickenhausen, Germany)
overnight at 4°C. Plates were washed three times with PBS-Tween
0.05%, and nonspecific binding was blocked for 2 h at 37°C with
0.2 M TRIS-HCl buffer (pH 7.5) containing 1% bovine serum
albumin and 0.05% Tween. Samples or standard (0.01-10 ng/
mL rIL-8; gift of M. Baggiolini, Theodor-Kocher-Institut, Bern,
Switzerland) were incubated in 0.1 M PBS with 0.5% FCS and
0.05% Tween for 2 h at room temperature. Plates were washed
four times with PBS-Tween, then alkaline phosphatase-labeled
monoclonal anti-IL-8 antibody (1.5 f.-lg/mL, gift ofP. Stuetz) was
added and incubated for 2 h at 3rC. After a wash, the substrate
p-nitrophenylphosphate (Sigma, St. Louis) was added for 1 h, and
the enzymatic reaction was terminated by the addition of 2 M
NaOH. Absorbance was read at 405 nm in an ELISA reader (Mo-
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Figure 1. Interleukin(IL)-8 release induced by 100 ng/mL Salmo-
nel/a abortus equi lipopolysaccharide (LPS) in 5% human pooled
serum from SW620 cells at different cell concentrations (0.5, I, 2,
and 4 X 105 cells/mL). 0, unstimulatedcells; _, LPS-stimulated cells.
Means (±SE) of 3-5 experimentsare shown. Regression analysis: r
= .987, P = .01.
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Figure 2. Dose-response curve of lipopolysaccharide (LPS) on in-
terleukin (lL)-8 release from SW620 cells without(0) or with 0.5%,
1.25%, 2.5%, or 5% serum: A, Salmonella abortus equi LPS. B,
Escherichia coli Re LPS. C, Lipid A. Means (±SE) from 3 experi-
ments are shown; values with 1-100 nglmL S. a. equi and E. coli
Re LPS as well as values with 10-100 ng/ml, lipid A were signifi-
cantly higher in presence than in absence of 5% serum. * P < .05,
** P = .01, *** P < .001.
Cell model used for the study ofsCD14 function. To mea-
sure sCD14 function in patient serum, the optimal assay condi-
tions had to be defined. Therefore, we identified the relation-
ships between cell number, serum concentration, LPS
concentration, and IL-8 response in the SW620 cells.
Figure 1 shows a linear dose-response of IL-8 production
on stimulation with 100 ng/mL LPS at cell concentrations be-
tween 0.5 and 4 X 105 cells/mL (r = .987, P = .01). Without
LPS, no IL-8 release was observed.
Since we wanted to investigate the effect of sCD 14 on an
LPS-dependent function in SW620 cells, we tested the dose
response of IL-8 with different LPS preparations and concen-
trations. LPS from S. a. equi (smooth LPS, figure 2A) and from
E. coli Re (rough LPS, figure 2B) induced a dose-dependent IL-
8 release in the presence of 5% human pooled serum. Values
peaked with 10 ng/mL smooth or rough LPS. LPS did not
cause any IL-8 liberation in the absence of serum. The influence
of the serum concentration is shown in figure 2A. At a subopti-
mal LPS concentration of 1 ng/mL, serum concentrations be-
tween 0.5% and 5% induced similar responses. In contrast, at
10 and 100 ng/mL LPS, the serum concentration was rate-
limiting for IL-8 production. Stimulation with lipid A led to
IL-8 production of lesser potency than did smooth or rough
LPS (figure 2C).
Since LPS requires serum to induce epithelial cell activation
[2] (figure 2), we determined the dose-response curve for serum
with a high nonlimiting dose of LPS. As shown in figure 3,
incubation of 100 ng/mL LPS in 0%-80% human pooled se-
rum (corresponding to 0-2.1 {lg/mL sCD14) led to IL-8libera-
tion with a bell-shaped dose-response curve. The maximal ef-
lecular Devices, Palo Alto, CA). Human pooled serum did not
contain detectable IL-8.
Endotoxin measurement. The endotoxin content in media,
rsCD14, and antibodies was "S 10 pg/mL as determined by a
limulus amebocyte lysate assay kit (Chromogenix, Molndal, Swe-
den).
Statistics. The results of the IL-8 assays in patients and con-
trols and of assays with LPS in the presence and absence of serum
were compared by analysis of variance and Scheffe's F test for
post hoc evaluation of statistically significantdifferences. The rela-
tionship between two parameters was assessed by simple regres-
sion.
Results
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Figure 3. Effect of different concentrations of complete pooled se-
rum (e), CDl4-depleted serum (.), and pooled serum with 10 /-lg!
mL anti-CDl4 antibody 3CIO (1':.) on interleukin (IL)-8 release in
SW620 cells stimulated with 100 ng/mL Salmonella abortus equi
lipopolysaccharide. Means (±SE) of 3-8 experiments are shown.
feet was reached at 20% serum, corresponding to 520 ng/mL
sCDI4. At higher serum concentrations (i.e., 40% and 80%),
the IL-8 response declined. LPS did not induce IL-8 release in
CDl4-depleted serum. At all serum concentrations, the LPS
effect was blocked by anti-CDl4 antibody 3CIO.
To further analyze the role of sCDl4 in LPS-induced IL-8
production, blocking experiments were done with anti-CDl4
JID 1996;173 (March)
antibodies. Figure 4 illustrates that LPS induced a similar
amount ofIL-8 with 5% human pooled serum (containing 130
ng/mL sCDl4) and with 140 ng/mL rsCDl4. In both, IL-8
production was blocked with anti-CD14 but not with control
mouse IgG antibody (data not shown for rsCD14 + IgG). The
5% CD14-depleted serum did not promote the LPS effect on
IL-8. Since the dose-response curve of serum was bell-shaped
(figure 3), we also tested rsCDI4 to see whether the same
phenomenon occurred in the absence of serum. Figure 5 shows
the dose-dependent IL-8 liberation with LPS and rsCDl4.
rsCDI4 caused increasing IL-8 release at concentrations be-
tween 10 and 100 ng/mL. The effect plateaued from 100 to
1000 ng/mL and declined between 2 and 10 ;.tg/mL rsCDl4.
On the basis of the above-described results in SW620 cells,
sCDI4 dependence ofIL-8 release in this model was demon-
strated at low serum and corresponding sCDI4 concentrations
and at high LPS concentrations. These conditions were used
to study patient sera.
Effect of serum from patients with septic shock or PNH
and from controls on LPS-induced lL-8 release. We have
previously noted elevated sCDI41evels in patients with gram-
negative septic shock compared with healthy controls (3.61 ::t::
02.6 vs. 2.48 ::t:: 0.81 ;.tg/mL) [10]. We extend this observation
to 16 patients with septic shock due to non-gram-negative
microorganisms (sCDl4, 4.01 ::t:: 0.61 ;.tg/mL). The 6 patients
with PNH and the II healthy controls had mean sCD14concen-
trations of 3.08 ::t:: 0.71 and 2.56 ::t:: 0.14 ;.tg/mL, respectively.
The values in patients with non-gram-negative sepsis were
significantly (P < .05) higher than in controls.
In the present study, the function of sCDI4 was assessed in
serum from 69 sepsis patients of both groups, from 6 patients
with PNH, and from II healthy controls. There were elevated
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Figure 5. Dose-response curves for effect of rsCD 14 on interleukin
(IL)-8 released with 100 ng/mL lipopolysaccharide (LPS). SW620
cells were treated with rsCDI4 alone (0), with LPS plus rsCDl4
(e), with LPS and rsCDl4 plus IgG (..), and with LPS and rsCDl4
plus anti-CDl4 (1':.).
ng/ml rsCD14
Figure 4. Interleukin (IL)-8 production in unstimulated (~) or lipo-
polysaccharide-stimulated (100 ng/mL Salmonella abortus equi, .)
SW620 cells. Cells were stimulated in medium with 5% complete
human pooled serum (HPS), CDl4-depleted serum (ABS), or 140 ng/
mL rsCDl4. Monoclonal anti-CDl4 antibodies (10 /-lg!mL 3CIO) or
control mouse IgG2b hybridoma supernatant (10 /-lg/mL) was added
to serum or rsCD14 before LPS stimulation. Means (±SE) of 4 experi-
ments are shown. HSA, human serum albumin.
o 10 100 1000 10000
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IL-8 levels in supernatants of unstimulated SW620 cells (73
:::'::: 24 pg/mL) from 6 of 53 patients with gram-negative sepsis
and 1 of 16 patients with non-gram-negative sepsis. This was
due to a high serum IL-8 concentration (78 :::'::: 13 ng/mL).
After LPS stimulation, IL-8 did not further increase in these
supernatants (74:::'::: 15 pg/mL). Therefore, these 7 patients were
excluded from further analysis.
Figure 6 shows the IL-8 release in the epithelial cell model
after stimulation with LPS and 0.5% serum from 47 patients
with septic shock due to gram-negative organisms (figure 6A),
15 patients with sepsis due to non-gram-negative organisms
(figure 6B), 6 PNH patients (figure 6C), and 11 healthy volun-
teers (figure 6D). Baseline IL-8 values did not differ statistically
among the 4 groups. Patient and control sera allowed LPS to
induce IL-8. Levels of LPS-induced IL-8 release were signifi-
cantly higher in patients with non - gram-negative sepsis (81
:::'::: 9 pg/mL) than in patients with gram-negative sepsis (43 :::':::
4.0 pg/mL, P < .001), PNH patients (20 :::'::: 3.9 pg/mL, P <
.001), or controls (34:::'::: 3.5 pg/mL, P < .001). This difference
was also observed in samples treated with LPS and the control
antibody. Among patients with gram-negative sepsis, those
with the 55-kDa isoform had a stronger LPS-induced IL-8
increase than those with the 49-kDa sCD14 (P = .02, data not
shown). There was no significant difference in the IL-8 re-
sponse between survivors and nonsurvivors. CD14 antibodies
blocked LPS-induced IL-8 secretion in all samples, whereas
control mouse IgG had no effect.
To confirm the dose-dependent effect of serum sCD14 in
LPS-induced epithelial cell activation, the relationship between
the IL-8 response and the sCD 14 concentration in the assay
(e.g., sCDl4 in 0.5% serum) was established. In patients with
gram-negative sepsis (n = 47; figure 7A, P = .02) or non-
gram-negative sepsis (n = 15; figure 6B, P = .01), the increase
in IL-8 with LPS stimulation correlated significantly with the
sCD 14 concentration. In gram-negative sepsis, only nonsurviv-
ing patients with the highest sCDl4 concentration contributed
to this relationship (nonsurvivors, r = .686, P < .001; survi-
vors, r = .242, not significant).
Discussion
The aim of the present study was to assess sCD 14 function
in sera of patients with septic shock. Sera from patients with
PNH and from healthy volunteers were used as controls to
measure the sCD 14-dependent LPS effect in vitro. An epithelial
cell line that responds to LPS with IL-8 release only in the
presence of sCD14 was used as a model. sCD14 binds LPS
and mediates its effects on cells devoid of membrane CD14
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Figure 7. Relationship between serum CD14 concentrations and
interleukin (lL)-8 response in SW620 cells. A, sCDI4 concentration
in 0.5% serumfrom47 patientswith gram-negative sepsis (0, survi-
vors; ., nonsurvivors; r = .686,P < .001, line of best fit drawn for
nonsurvivors only). B, 0.5% serumfrom 15patients withnon-gram-
negative sepsis (D, survivors; _, nonsurvivors; r = .632,P < .01).
[2, 6]. The dose-response curve for the LPS-sCDl4-induced
IL-8 release from epithelial cells has hitherto not been de-
scribed. In particular, the potency of sCD14 at its normal serum
concentration is unknown.
Therefore, we obtained dose-response curves with serum con-
taining sCDI4. We established that sCD14 activates epithelial
cells with a bell-shaped dose-response curve. The maximal re-
sponse occurred at 20% serum, corresponding to 500 ng/mL
sCDI4. At higher serum concentrations, LPS-induced IL-8 pro-
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duction was weaker. This may have been due to a serum inhibitor,
such as serum lipoproteins, which are known to neutralize LPS-
sCDl4 complexes [25]. However, a bell-shaped curve was also
observed with rsCDl4, with an optimal response at 100-1000
ng/mL and a weaker effect at 10 fLg/mL. Thus, rsCD14 was
similar in potency to serum CDl4. This finding, with LPS and
CD14 in the absence of serum proteins, indicates that our experi-
ments were done at an optimal ratio between LPS and CDI4.
Serum contains LPS-binding protein (LBP), which enhances
LPS affinity to myeloid, endothelial, or epithelial cells [26,
27]. We could exclude the role of LBP in our model, as LBP
displays its activity only at low LPS concentrations [2, 27],
and we used a high LPS concentration. This is in agreement
with other observations of an LBP-independent sCD 14-depen-
dent adherence molecule expression by LPS in endothelial cells
[27]. In addition to its agonist effect on epithelial cells, rsCDl4
has been shown to neutralize LPS-induced tumor necrosis fac-
tor (TNF) release in human blood and chemiluminescence from
monocytes at doses of 10-1 00 fLg/mL [9, 28]. In view of this
dual role of sCD14 in vitro, it was interesting to test sCD14
function in sera from patients with septic shock ex vivo.
We first determined model conditions under which sCDl4
and not LPS determined the IL-8 release. We found a dose
dependence for sCDl4 only at high LPS and low sCDl4 con-
centrations (15-500 ng/mL) corresponding to 0.5%-20% se-
rum. Since sepsis patients had normal or increased serum
sCDl4 levels with up to 5-fold higher values than controls, we
used a low serum concentration to show an sCD14-dependent
effect. Sera from patients and controls were effective in stimu-
lating IL-8 release. This response was dependent on sCDI4,
because it was blocked by anti-CDl4 but not by an irrelevant
mouse antibody, and it was significantly related to the sCDl4
concentration in serum.
Patients with non-gram-negative sepsis had the highest
sCD14 serum levels and the strongest sCD 14-dependent IL-8
response. This shows that the increase of serum sCD14 we
observed in gram-negative sepsis was not specific for this dis-
ease and not induced by LPS [10]. It has recently been found
that sCD14 not only binds to LPS but also to cell wall compo-
nents from gram-positive microorganisms or mycobacteria [7,
29-31]. Therefore, probably not only LPS but also other bacte-
rial components can cause an increase in serum sCDI4. Alter-
natively, an intermediate product that is induced by gram-nega-
tive and other microorganisms induces the rise of serum CD14.
Since we showed that IL-8 response correlated with serum
CD 14 concentration, sCD14 may represent the common media-
tor of epithelial [19] or endothelial cell effects [32] in sepsis
due to different microorganisms. This hypothesis is sustained
by earlier observations of elevated CD14 levels in serum or
bronchoalveolar lavage fluid of infectious patients with poly-
trauma, bums, or adult respiratory distress syndrome [33, 34].
The fact that the IL-8 response was stronger in gram-positive
or fungal sepsis patients than in gram-negative sepsis patients
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may indicate that in the former group, sCD14 activity was not
neutralized by lipoproteins [25].
sCD14 from the patients was also tested to determine
whether the predominance of one or the other sCD14 isoform
(49 or 55 kDa) was associated with a different functional capac-
ity. CDl4 mediated the LPS effect irrespective ofthe predomi-
nant isoform. Although there was a higher response in the
patients with the 55-kDa form than in those with the 49-kDa
form, the difference was modest, and in all patients, the func-
tion was dependent on the sCD14 level. If the 55-kDa form
differed in its functional capacity, sCD14 levels would not
correlate with the IL-8 response in patients with the highest
serum sCDI4 level, who exclusively expressed the 55-kDa
form.
Moreover, the difference would have been evident in the
sera from PNH patients, in which we detected exclusively the
55-kDa isoform. Other authors, by using 12.5% polyacrylamide
gels under reducing conditions and Western blot analysis of
serum CDI4, observed both isoforms in patients with PNH and
in controls [14]. In our system, under nonreducing conditions
in 7.5% polyacrylamide gels, we detected only the smaller
form in healthy controls and the larger form in PNH patients
and sepsis patients with high sCDl4levels. Thus, the predomi-
nant isoforms that we detected in each group did not appear
to differ in their functional capacity. Since the two isoforms
differ in their C terminal only, this result was expected. It has
recently been shown that sCD14 from which two-thirds of the
carboxy-terminus is deleted retains bioactivity [35].
Endothelial cells are activated not only by LPS but also, and
more strongly, by the secondary mediators TNF and IL-I [2].
Thus, sCD14 may serve purely as an initial trigger when LPS
concentrations are very high. Alternatively, the direct LPS-
sCD14 activation pathway may become important at a later
stage of sepsis, when myeloid cells are adapted (i.e., when they
no longer respond to LPS with a strong cytokine response).
Moreover, it is possible that LPS-sCD 14 complexes are activa-
tors of epithelial cells in the extravascular space, where myeloid
cells are rare.
In conclusion, we have obtained evidence that sCD14 in
serum from patients with septic shock activates epithelial cells
in the presence of LPS. In this model we could not detect any
LPS-neutralizing role of sCDI4.
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